Upgrade to SI Premium - Free Trial

JPMorgan Starts Kura Oncology (KURA) at Overweight

October 1, 2026 2:43 AM
JPMorgan analyst Priyanka Grover initiates coverage on Kura Oncology (NASDAQ: KURA) with a Overweight rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments New Coverage